Apnimed presents Phase 3 AD109 obstructive sleep apnea data at CHEST 2026
Apnimed flagged five CHEST 2026 presentations tied to its Phase 3 program for investigational oral OSA drug AD109. Data will be presented Oct. 20-21 in Phoenix, including late-breaking analyses in post-menopausal women and blood-pressure response markers. Another Phase 3 presentation will cover patient-reported outcomes, aiming to support broader assessment of treatment benefit beyond standard sleep metrics. A CHEST panel will review Phase 3 SynAIRgy and LunAIRo trial results, framing potential implications for future OSA management. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apnimed Inc. published the original content used to generate this news brief via (Ref. ID: 202610121605PRIMZONEFULLFEED9843252) on October 12, 2026, and is solely responsible for the information contained therein. (C)
Apnimed flagged five CHEST 2026 presentations tied to its Phase 3 program for investigational oral OSA drug AD109. Data will be presented Oct. 20-21 in Phoenix, including late-breaking analyses in post-menopausal women and blood-pressure response markers. Another Phase 3 presentation will cover patient-reported outcomes, aiming to support broader assessment of treatment benefit beyond standard sleep metrics.
A CHEST panel will review Phase 3 SynAIRgy and LunAIRo trial results, framing potential implications for future OSA management. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apnimed Inc.
published the original content used to generate this news brief via (Ref. ID: 202610121605PRIMZONEFULLFEED9843252) on October 12, 2026, and is solely responsible for the information contained therein. (C)